首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
【24h】

MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.

机译:MicroRNA-21在胰腺导管腺癌前体病变的早期诱导。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the poorest overall prognosis among gastrointestinal cancers; however, curative resection in early-stage PDAC greatly improves survival rates, indicating the importance of early detection. Because abnormal microRNA production is commonly detected in cancer, we investigated noninvasive precursor pancreatic intraepithelial neoplasia (PanIN) lesions for microRNA production as a potential early biomarker of PDAC. METHODS: Pathologists identified and classified ductal lesions. We extracted total RNA from laser-capture microdissected PanIN tissue samples from a conditional KRAS(G12D) mouse model (n = 29) or of human origin (n = 38) (KRAS is v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). MicroRNA production was quantified by quantitative real-time PCR. Internal controls included 5S and U6 RNAs. RESULTS: Production of microRNAs miR-21, miR-205, and miR-200 paralleled PanIN progression in the KRAS(G12D) mouse model, compared with microRNA production in samples of nonpathologic ducts. miR-21 demonstrated the highest relative concentrations in the precursor lesions. Interestingly, miR-205 and miR-21 up-regulation preceded phenotypic changes in the ducts. The production of microRNAs miR-21, miR-221, miR-222, and let-7a increased with human PanIN grade, with peak production occurring in hyperplastic PanIN-2/3 lesions. In situ hybridization analysis indicated miR-21 production to be concentrated in pathologic ductal cells. miR-21 production was regulated by KRAS(G12D) and epidermal growth factor receptor in PDAC-derived cell lines. CONCLUSIONS: Aberrant microRNA production is an early event in the development of PanIN. Our findings indicate that miR-21 warrants further investigation as a marker for early detection of PDAC.
机译:背景:胰腺导管腺癌(PDAC)在胃肠道癌症中的总体预后最差。然而,早期PDAC的根治性切除术大大提高了生存率,表明了早期发现的重要性。由于通常在癌症中检测到异常的microRNA产生,因此我们调查了非侵入性前体胰腺上皮内瘤变(PanIN)病变,以产生microRNA作为PDAC的潜在早期生物标记。方法:病理学家确定并分类了导管病变。我们从有条件的KRAS(G12D)小鼠模型(n = 29)或人类起源(n = 38)的激光捕获显微切割的PanIN组织样品中提取了总RNA(KRAS是v-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物) 。通过定量实时PCR定量MicroRNA生产。内部对照包括5S和U6 RNA。结果:与非病理性导管样本中的microRNA产生相比,在KRAS(G12D)小鼠模型中microRNA miR-21,miR-205和miR-200的产生与PanIN的进展平行。 miR-21在前体病变中显示出最高的相对浓度。有趣的是,miR-205和miR-21的上调先于导管的表型改变。 microRNA miR-21,miR-221,miR-222和let-7a的产生随人类PanIN等级的增加而增加,增生性PanIN-2 / 3病变中产生峰值。原位杂交分析表明,miR-21的产生集中在病理性导管细胞中。在PDAC衍生的细胞系中,miR-21的产生受KRAS(G12D)和表皮生长因子受体的调节。结论:异常的微小RNA生产是PanIN开发的早期事件。我们的发现表明,miR-21作为早期检测PDAC的标记值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号